Therapeutic Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a novel class of medications for managing dyslipidemia. Although previous meta-analyses have confirmed their efficacy in lowering low-density lipoprotein cholesterol (LDL-C), few have evaluated their effects on br...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Nur Hafidha Hikmayani, Ratih Puspita Febrinasari, Ariq Ratya Satwika
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Universitas Padjadjaran 2025-09-01
coleção:	Althea Medical Journal
Assuntos:	alirocumab cholesterol dyslipidemia evolocumab pcsk9 inhibitors
Acesso em linha:	https://journal.fk.unpad.ac.id/index.php/amj/article/view/4209
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!